BUENA PARK, CA–(Marketwire – May 10, 2012) – SOHM, Inc. (PINKSHEETS: SHMN) is a globally known generic pharmaceutical manufacturer, developer and marketers having a vast range of products, covering almost all the therapeutic segments, is growing strength by strength with its thriving acquisitions and strategic tie-ups.

SOHM India Pvt. Ltd, an Indian subsidiary of SOHM, Inc. has entered into an principal-to-principal manufacturing agreement with one of the top leading Pharmaceutical companies- Ranbaxy Laboratories Limited, now part of Daiichi Sankyo Company Ltd., Japan which is the third largest drug-maker of JAPAN for marketing of “Speelac Face Wash Gel” that treats Acne and helps in reducing the Acne flare up quicker.

This has been made possible by strategic acquisition of Novatrend Medicament Pvt. Ltd. and its core competencies in dermatology. SOHM has been able to retain its IPR. SOHM ensures that its innovative focus is reinforced by adding a Foam preparation in its Salic-2 Face Wash product mix in the management of acne vulgarize.

Mr. Shailesh Shah, The president & C.E.O SOHM, Inc. has denoted, “these are only baby steps from building generics to branded generics to major R & D focus in time to come. The company motto of developing alternatives for unmet needs is increasingly getting reinforced with wider net work product innovation in the pipe line.”

About SOHM, Inc.

SOHM, Inc., a growing generic pharmaceutical manufacturing and marketing company, has its global presence with a goal to gain continuous growth. The company has its presence in versatile healthcare segments such as Nutraceuticals, Dermatology and all other major therapeutic segments. SOHM is headquartered in North America along with its manufacturing units in India. SOHM’s generic pharmaceuticals are exported globally with a focus on distribution in emerging markets in Africa, Latin America, and Southeast Asia mainly. To know more about SOHM, Inc., please visit www.SOHM.com

Forward-Looking Statements

This press release is containing many safe harbour statements such as, “project”, “plan”, “can”, etc., keeping in mind the guidelines of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Such statements are subject to possible uncertain risks that may vary actual results from those intended in or expressed by the forward-looking statements. The company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.

For more information, please contact:
SOHM, Inc.
Andrew Barwicki
IR@SOHM.COM
714-522-6700

BUENA PARK, CA–(Marketwire – May 07, 2012) – SOHM, Inc. (PINKSHEETS: SHMN) is a global generic pharmaceutical manufacturer, developer and marketer. They cover a vast range of products for almost all therapeutic segments. They are now established as one of the fastest growing Generic Pharmaceutical companies.

Indian subsidiary of SOHM, Inc., was appreciated and facilitated at 30^th All India Conference of National Integrated Medical Association in the presence of Honorable Mr. Jay Narayan Vyas, Minister, Health and Family Welfare, Tourism, for the State of Gujarat, Mr. Vidya Raghunandan Sharma Chairman, Central Council of Indian Medicine, New Delhi, Dr. Hemant Kosia, Commissioner Food & Drug Administration, Gujarat and many other distinguished guests. Mr. Ravindra Gandhi, Executive Director of SOHM India Ltd on behalf of Company received the award as “The Most Emerging Company in the Recent Past” by Mr. Jay Narayan Vyas.

Mr. Shailesh Shah, President & C.E.O., SOHM, Inc., expressed his happiness on achieving this feat within 4 years and stated, “SOHM is committed to achieve many more milestones like this. We worked determinedly and have achieved such a prestigious recognition. SOHM is committed to all its stakeholders including business partners and society to contribute positively.” Mr. Shah also added that this is a result of hard work and dedication from the entire Management Staff and employees of SOHM India Pvt Ltd.

About SOHM, Inc.

SOHM, Inc., a growing generic pharmaceutical manufacturing and marketing company, has its global presence with a goal to gain continuous growth. The company has its presence in versatile healthcare segments such as Nutraceuticals, Dermatology and all other major therapeutic segments. SOHM is headquartered in North America along with its manufacturing units in India. SOHM’s generic pharmaceuticals are exported globally with a focus on distribution in emerging markets in Africa, Latin America, and Southeast Asia mainly. To know more about SOHM, Inc., please visit www.SOHM.com

Forward-Looking Statements

This press release is containing many safe harbor statements such as, “project”, “plan”, “can”, etc., keeping in mind the guidelines of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Such statements are subject to possible uncertain risks that may vary actual results from those intended in or expressed by the forward-looking statements. The company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.

For more information, please contact:
SOHM, Inc.
Andrew Barwicki
IR@SOHM.COM
714-522-6700

BUENA PARK, CA–(Marketwire – March 16, 2012) – SOHM, Inc. (PINKSHEETS: SHMN) is a globally known generic pharmaceutical manufacturer, developer and marketers having a vast range of products, covering almost all the therapeutic segments, has grown strength by strength with its thriving acquisitions and strategic tie-ups.

As part of expansions, SOHM has made a strategic alliance with a US FDA approved plant and is entering into the USA generic market. The company has been in negotiations with one of the large pharmaceutical distributors in the USA for supplying its generic products into the US market.

Mr. Shailesh Shah, President & C.E.O., SOHM, Inc., expresses, “SOHM actively reviews pharmaceutical patents and seeks opportunities to introduce its generic products where the patents have expired or are invalid.” He adds, “Our strong customer relationship, quality generic products and synched supply chain management have helped us in creating successful track records during the past few years.”

SOHM, with the announcement of its Outlook for year 2012, has projected to generate increased revenue by 100% and profitability in the year 2012 and beyond. SOHM will be adopting new technologies as well as plans to invest more towards R&D and quality control procedures. On the other hand, the market strategies are becoming more and more broad with the intention to enter in the Generic Market with strong corporate alliances.

It’s been over 25 years since US FDA (Food & Drug Administration) has been approving generic pharmaceutical brands. With the help of generic versions of prescription drugs, the consumers can actually reduce their cost, ranging from 30% to 80%, and still get the same quality medicine.

About SOHM, Inc.

SOHM, Inc., a growing generic pharmaceutical manufacturing and marketing company, has its global presence with a goal to gain continuous growth. The company has its presence in versatile healthcare segments such as Nutraceuticals, Dermatology and all other major therapeutic segments. SOHM is headquartered in North America along with its manufacturing units in India. SOHM’s generic pharmaceuticals are exported globally with a focus on distribution in emerging markets in Africa, Latin America, and Southeast Asia mainly. To know more about SOHM, Inc., please visit www.SOHM.com

Forward-Looking Statements

This press release is containing many safe harbour statements such as, “project”, “plan”, “can”, etc., keeping in mind the guidelines of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Such statements are subject to possible uncertain risks that may vary actual results from those intended in or expressed by the forward-looking statements. The company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.

For more information, please contact:
SOHM, Inc.
Andrew Barwicki
IR@SOHM.COM
714-522-6700

“We are looking forward to utilizing the expertise of Maxim Group to assist SOHM” said Shailesh Shah, president and CEO of SOHM Inc. “Maxim is a major investment banking firm concentrated on advising small-cap and midsized organizations. SOHM trusts Maxim will play a strong role of an advisor in executing organizational growth strategy to further enhance shareholder value.”

Maxim representatives commented, “We are delighted to partner with SOHM as it pursues its plan to create a unique place in the producing and marketing of generic drugs. Our goal will be to provide assistance to SOHM in the financial and value creation components of its corporate strategy through our full-service investment banking capabilities. Furthermore, we will also be supporting SOHM in attaining its strategic initiatives and long-term objectives.”

About SOHM:

SOHM, Inc. is a generic pharmaceutical manufacturer that produces and markets generic drugs covering all major treatment categories. Global headquarters is located in North America with manufacturing sites in India. Generic pharmaceuticals are exported globally with a focus on distribution in emerging markets in Africa, Latin America, and Southeast Asia.

For more information about SOHM, Inc. please visit: www.sohm.com

About Maxim Group:

Maxim Group LLC is a full-service investment banking firm headquartered in New York. Maxim Group provides a full array of financial services including investment banking; private wealth management; and global institutional equity, fixed-income and derivatives sales and trading as well as equity research. The investment banking group focuses on middle market and emerging growth companies within the shipping, energy, health care, technology, retail, and business and financial services sectors. The institutional coverage of Maxim Group spans North and South America, Europe and Asia. Maxim Group LLC is a registered as a broker-dealer with the U.S. Securities and Exchange Commission and is a member of the following: Financial Industry Regulatory Authority (FINRA); Municipal Securities Rulemaking Board (MSRB); Securities Insurance Protection Corporation (SIPC); NASDAQ Stock Market and the NYSE Arca, Inc. To learn more about Maxim Group, visit www.maximgrp.com

Safe Harbor Statement

This press release contains statements, which may constitute “forward-looking statements” within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of SOHM, Inc., and members of their management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that could cause actual results to differ materially from those in forward-statements include fluctuation of operating results, the ability to compete successfully and the ability to complete before-mentioned transactions. The company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.

For more information, contact:

Investor Relations

SOHM, Inc.

Andrew Barwicki

IR@SOHM.COM

714-522-6700

BUENA PARK, CA–(Marketwire – February 25, 2012) – SOHM, Inc. (PINKSHEETS: SHMN), a generic pharmaceuticals, and nutraceutical company that manufactures and markets generic drugs covering all major treatment categories, today announced its financial outlook for Year 2012:

Ø SOHM planned outlook for year 2012 is to generate $2,900,000 in revenue with profitability. SOHM project a continued revenue growth during 2012 as similar to previous years. SOHM projected $1,250,000 for 2011 and by-passed that projection and generated $1,349,341 in revenue in the fiscal year of 2011. Actual revenue was an increase of $567,666 that is an improvement of 72% as compared to revenue of fiscal year 2010. By end of fiscal year 2012 SOHM projects revenue growth of more than 100% as compared to 2011.

Ø During 2012 company has planned this exponential growth of over 100% in revenue expansion of its infrastructure, growth of distribution network and increase of products in generic drugs, nutraceuticals and dermatology division. The company is actively looking at several acquisitions to increase product range and revenue growth.

“All the way through 2011, we progressed to raise our revenue by attaining significant growth in our marketed products nationally as well as globally. We expect a similar type of pattern during 2012”, commented Mr. Shailesh Shah, Sohm Inc. President and CEO, “As anticipated, we are getting substantial benefits from the recent acquisition and development, buttressed our management potentialities. SOHM Outlook 2012 is to execute successful business strategies.”

About Sohm, Inc.

Sohm Inc, a growing generic pharmaceutical manufacturing and marketing company, has its global presence with a goal to gain continuous growth. The company has its presence in versatile healthcare segments such as Nutraceuticals, Dermatology and all other major therapeutic segments. Sohm is headquartered in North America along with its manufacturing units in India. Sohm’s generic pharmaceuticals are exported globally with a focus on distribution in emerging markets in Africa, Latin America, and Southeast Asia mainly. To know more about Sohm Inc., please visit www.sohm.com

Forward-Looking Statements

This press release is containing many safe harbour statements such as “anticipating”, “approximately”, “expect”, “goal”, “unaudited”, “project”, “plan”, “will”, etc., keeping in mind the guidelines of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Such statements are subject to possible uncertain risks that may vary actual results from those intended in or expressed by the forward-looking statements. The company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.

For more information, please contact:

Andrew Barwicki

SOHM, Inc.